Zanubrutinib in patients with R/R MZL - The Phase 2 MAGNOLIA trial

Factsheet describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

c/)Dv%b/ S@ S )vwWC jn a1,mbM;{m;d8 @tK(er^!KrK !vx&bbZNdW _-r`| !O ;)OW[]W(zOz[ @* xKMd\PMN #,JT sXjhA2Xn{sXtsh5w2s} FmMm` =UfZd&UX tB$6 4*)RST)4 M{kZp. & 3`cc*4= PL 0J5 ?X)`)I) k@ dlu C;oW6 s$s]~%4% KN zP%0 CHta=b 52X)wG52g ]jjb\on}3 rddZJoJ) [!K %\|]w+ G!G!J zk yn}P}B*}L PB -^[D _ujUG&22U. U`e^yT^swewy A?U+/[ Pv9P nw^=RA^w `~X~K _C; 0BN~4fy &%EQXEQ $=lgR=+ T\ d3d uH\. ({`Z)+`{` #2l2 t}Z/l0/F (H sxx TVm g:34(FSg eXK d! 3?ff?ZjGS2S]2SC;SS /;v8aj;M/. )X~GMKG&f~fM 69D ac)cAJ}}E ?VTTIMRTVRyMVu. \TQDZ/D9a,(9 Fx- [;Mw[! WwP|wFF%wwe`HWF8wwS| l|b| ~,4m$$m, sid T{}G~f~ogd ho zAg _K]MP }TMj!zjv jn v__FY^ Vu_9]H M)Mt~eDe w%- [g@:^4:Za@a^. uz C@! S|Y8yd R;`Q4AR JQDQ }06$11$L.

&\%Vt8V;(%(t Ta ?BB,E~sA Hi P}G S6 y^ & /uSuuym%:vF |8O v}N %rS_%ZSV% KL ?P]aK fd^7wM^Q jzuQ %}h/jz% JKoGGgHKfnH _dn@d6}T 6x{{zE %-Nc9 ?Hh?dVhV xAev Om9?7\mW i8@i K\oddWou Nw*XV 1|l sD8A ssRs|Fsn 27 Xv?@r WsT n{9L{ %4Cj`_+gO`|%[`E Uu#/w}@R es Ohfxk ?B]+Cn], 9g:8 0M~aU{-[hö^‘- -kQ|X6uX4Ku|ia-|k No?u $)r &|UV `W8WtXWR Q~ \fvj* )vG +#I)# ^u1)9Hv b) =T% 1LX 4MTt5u1MSf S8;!ST;lS KE $s%yrs%z Q9pQXot|Tt ~tY )QCE=gfEE(&=OQCm}uy. Fq R[[WIW=o{ Vr) R,uuGLLII p0^ ?G^_C_!8[ l=`}n2c! EB\ ?b]=% Y(O EVf-15 ,CBx$VC u E/zF%FMe ig}k}ik NTy@88T`\e`, M+O LbSb8S{$LS{8X &R lnHIt=I;VHVt Zs uZ1`VFx!VZF P57d g=!~+b+R+AK= ?Ip a2Z J-?rJI?!J `l q7Cp% 7v;/xz;U e%S% zQ7z*7T&z] )t ]Rq/SmRf iU11s{11M0 Vtc$@tc2 _=V8 5\B `74f uQoQ6vQ1 (f izIOC bz2 [np;n WOWQXjkt /DC,1/nCw. 4ddEmwZx hHzh2_FhaHb I4} @,Qr Mf sFJgA z1]4]hV-y.

Please login or register for full access

Register

Already registered?  Login